Biovision Ventures

Biovision Ventures is a venture capital firm specializing in early-stage investments within the life sciences and healthcare sectors. The firm is dedicated to translating groundbreaking science into transformative therapies, focusing on private companies in the United States and Europe. Their investment approach is agnostic to specific diseases and modalities, prioritizing companies developing novel platform-based therapeutic approaches with strong intellectual property protection or hard-to-replicate know-how addressing unmet clinical needs.

The firm's investment strategy encompasses a broad range of sectors, including therapeutics, bioinformatics, medical software solutions for clinical use, and computational solutions for drug discovery and development. Biovision Ventures prefers to invest from Series Seed to Series B stages, aiming to lead or co-lead investments as part of a strong syndicate. They are active investors, often holding board positions to provide strategic guidance and support to their portfolio companies.

Biovision Ventures has built a diversified portfolio of breakthrough technologies and a track record of successful exits. Their portfolio includes companies like Arda Therapeutics, Diagonal Therapeutics, Elucid Bioimaging, and Tune Therapeutics. The firm's team comprises professionals with deep expertise in science, technology, healthcare, venture investment, and market access, complemented by key opinion leaders at the top of their fields. This combination enables Biovision Ventures to effectively support innovative companies in translating scientific advancements into impactful healthcare solutions.